10-K: MannKind Reports Strong Revenue Growth, Strategic Acquisitions

MannKind Corporation reported a 22% increase in total revenue for 2025, driven by product sales and collaborations, alongside strategic acquisitions and pipeline advancements.

Summary

• Total revenues for the year ended December 31, 2025, increased by 22% to $349.0 million, up from $285.5 million in 2024.
• Net income for 2025 was $5.9 million, a decrease from $27.6 million in 2024, primarily due to increased operating expenses and impairment losses.
• Commercial product sales grew by 39% to $114.1 million in 2025, compared to $82.3 million in 2024.
• Afrezza net revenue increased by 16% in 2025, driven by increased price and higher demand, with gross-to-net adjustments improving to 32% from 35%.
• Furoscix, acquired in October 2025, generated $23.2 million in net revenue from its acquisition date to December 31, 2025.
• V-Go net revenue decreased by 10% in 2025, primarily due to lower demand, despite improved gross-to-net adjustments.
• Collaborations and services revenue increased by 6% to $106.7 million, mainly due to increased manufacturing volume for Tyvaso DPI sold to United Therapeutics.
• Royalty revenue from United Therapeutics for Tyvaso DPI increased by 25% to $128.1 million in 2025.
• Research and development expenses increased by 45% to $66.3 million in 2025, largely due to the ICoN-1 clinical study (discontinued in Q4 2025), MNKD-201 clinical production scale-up, and Furoscix ReadyFlow expenses.
• Selling, general and administrative expenses rose by 53% to $144.1 million, reflecting $17.6 million in Furoscix promotion and support costs, $9.7 million in scPharma acquisition-related costs, and higher headcount.
• MannKind acquired scPharmaceuticals Inc. in October 2025 for a total deal value of up to $363.5 million, including cash and contingent value rights (CVRs).
• The company drew $325.0 million in term loans under the Blackstone Credit Facility in August and October 2025.
• As of December 31, 2025, cash, cash equivalents, and investments totaled $176.4 million, with outstanding borrowings of $361.3 million.
• The company had an accumulated deficit of $3.2 billion and a total stockholders' deficit of $51.0 million as of December 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and pipeline progress are positive, the significant decline in net income due to increased expenses and impairment, coupled with the competitive threat from a key partner, introduces notable concerns.

Positives

• Total revenues increased by 22% year-over-year, reaching $349.0 million in 2025.
• Commercial product sales saw a significant 39% increase, driven by Afrezza and the new Furoscix product.
• Afrezza net revenue grew by 16%, benefiting from increased price and higher demand, along with improved gross-to-net adjustments.
• The acquisition of scPharmaceuticals Inc. in October 2025 added Furoscix, a novel FDA-approved subcutaneous loop diuretic, to the commercial portfolio, generating $23.2 million in net revenue in Q4 2025.
• Royalty revenue from United Therapeutics for Tyvaso DPI increased by 25%, indicating strong commercial performance of the partnered product.
• Expansion of the collaboration with United Therapeutics for MNKD-1501, including an upfront payment and eligibility for future milestone payments and royalties.
• Positive safety and tolerability results from the Phase 1 clinical study of MNKD-201 in healthy volunteers.
• FDA conducted an unannounced GMP inspection of the Danbury facility in October 2025, concluding without any observations requiring a Form 483, affirming manufacturing quality.
• The company generated $18.3 million in cash from operating activities in 2025.
• Reversed $5.0 million of its valuation allowance on deferred tax assets due to the scPharma acquisition, strengthening evidence for realizability of NOLs and credit carryforwards.

Negatives

• Net income significantly decreased from $27.6 million in 2024 to $5.9 million in 2025, despite revenue growth.
• V-Go net revenue decreased by 10% in 2025 due to lower demand.
• Research and development expenses increased by 45%, partly due to the discontinuation of the ICoN-1 clinical study for MNKD-101 in Q4 2025.
• Selling, general and administrative expenses increased by 53%, including $9.7 million in transaction-related costs for the scPharma acquisition.
• Experienced a $7.7 million loss on foreign currency transactions in 2025, compared to a $3.9 million gain in 2024, due to U.S. dollar to Euro exchange rate fluctuations.
• Interest income, net, decreased by $4.6 million due to lower average balances on the securities portfolio and lower yields.
• Interest expense increased by $1.8 million due to new term loans with an aggregate principal amount of $325.0 million.
• Incurred a $6.4 million impairment loss on the Thirona investment in 2025 following cessation of its operations.
• Accumulated deficit remains substantial at $3.2 billion, and total stockholders' deficit was $51.0 million as of December 31, 2025.

Risks

• Commercial success of products (Afrezza, Furoscix, V-Go, Tyvaso DPI) may be limited, impacting revenue generation.
• United Therapeutics may reduce commercial emphasis on Tyvaso DPI, potentially prioritizing its own Tresmi product, which could materially decline MannKind's royalty revenues.
• Manufacturing risks, including production difficulties, capacity utilization, yields, and compliance with regulations, may adversely affect the ability to manufacture products and Tyvaso DPI, reducing gross margin and profitability.
• Reliance on single-source suppliers for critical raw materials (e.g., insulin from Amphastar, FDKP, Furoscix components, V-Go components) poses risks of supply disruption, increased costs, and regulatory non-compliance.
• International trade policies, including tariffs and trade barriers (e.g., U.S.-China trade relations affecting V-Go manufacturing in China), may adversely affect business, financial condition, and results of operations.
• If third-party payers do not cover approved products or reduce reimbursement levels, product prescription, use, or purchase could be adversely affected, impacting revenues.
• Need to raise additional capital to fund operations, which may be difficult to obtain on favorable terms or at all, potentially leading to dilution or operational curtailment.
• Compromise of data or information technology systems (or those of third parties) could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Operating results are expected to fluctuate, making future performance difficult to predict.
• May incur future losses and may not generate sufficient cash flow from operations to service indebtedness and commitments.
• Continued testing of product candidates may not yield successful results, or long-term safety/efficacy of approved products may differ from clinical studies, negatively impacting sales and reputation.
• Products and technology may not compete effectively or may be rendered obsolete by new developments (e.g., Tresmi vs. Tyvaso DPI).
• The Blackstone Credit Facility contains restrictive covenants and liquidity requirements ($40.0 million minimum), and a default could materially and adversely affect financial position.
• Failure to realize anticipated benefits from the scPharma acquisition or future acquisitions, or difficulties in integrating new products/businesses.
• Changes in funding or staffing for regulatory agencies (FDA, SEC) could hinder timely product development or commercialization.
• Unstable market, economic, and geopolitical conditions (e.g., inflation, trade wars, conflicts) may adversely affect business, financial condition, and stock price.
• Product liability claims could result in significant liabilities and reputational damage, with current insurance coverage potentially inadequate.
• Loss of key employees could materially harm operations and business strategy.
• Internal controls over financial reporting may not be effective, leading to loss of public confidence.
• Changes in tax laws or regulations (e.g., OBBBA, IRA) may adversely affect business, cash flow, and results of operations, including limitations on net operating loss carryforwards.
• Dealing with hazardous materials and complying with environmental laws can be expensive, with potential liability for accidental contamination not fully covered by insurance.
• Maintaining cash balances at financial institutions that exceed federally insured limits poses a risk of loss if institutions fail.

Future Outlook

MannKind anticipates two potential milestones in 2026 for its cardiometabolic business: an FDA approval for Afrezza in children and adolescents (PDUFA target action date of May 29, 2026) and approval for the Furoscix ReadyFlow Autoinjector (PDUFA target action date of July 26, 2026). Top-line data for the MNKD-201 Phase 1b study is expected in early 2H 2026, with the first patient enrollment in a global Phase 2 study for IPF expected in Q2 2026. The company is also exploring MNKD-701, a bumetanide dry-powder formulation. United Therapeutics anticipates shifting primary manufacturing for Tyvaso DPI to its own facility beginning in 2026, with MannKind continuing as a secondary manufacturer. United Therapeutics also plans to file for approval of Tresmi, a treprostinil solution for a soft mist inhaler, within the year and launch commercially in the following year, which could impact Tyvaso DPI sales.

Management Comments

• We believe that our Connecticut facility has enough capacity to satisfy the current demand for Afrezza and Tyvaso DPI, especially given the recent expansion of our production capacity in order to meet the demand for Tyvaso DPI projected by UT over the next several years.
• We believe that our current third-party manufacturers have sufficient capacity to manufacture Furoscix in quantities sufficient to meet our expected commercial needs.
• We believe that, if necessary, alternative sources of supply for such components (V-Go single-source parts) would be available in a relatively short period of time and on commercially reasonable terms once such alternate suppliers have the appropriate tooling in place.
• We believe relations with our employees are good.
• We believe we will be able to meet our near-term liquidity needs based on our cash, cash equivalents and investments on hand, sales of Afrezza, Furoscix and V-Go, and royalties and manufacturing revenue from the production and sale of Tyvaso DPI as well as through debt or equity financing, if necessary, for our long-term liquidity needs.

Industry Context

StockSavvy.ai notes that MannKind's strategic focus on cardiometabolic and orphan lung diseases aligns with growing market needs for innovative, patient-centric solutions. The acquisition of scPharma and its Furoscix product positions MannKind in the heart failure and chronic kidney disease market, a segment with significant unmet needs for at-home treatment options. The expansion of the collaboration with United Therapeutics for MNKD-1501 further diversifies MannKind's pipeline in orphan lung diseases, leveraging its Technosphere platform. However, the potential introduction of Tresmi by United Therapeutics, described as a 'category killer' for dry-powder inhalers, poses a significant competitive threat to Tyvaso DPI, which is a major revenue driver for MannKind. This highlights the inherent risks of relying heavily on a single collaboration partner and the rapid pace of innovation in the pharmaceutical industry.

Comparison to Industry Standards

• Afrezza competes with rapid-acting insulin analogs from major global pharmaceutical companies like Eli Lilly and Company, Novo Nordisk A/S, and Sanofi S.A. MannKind's focus on an inhaled, ultra rapid-acting insulin offers a differentiated delivery method.
• V-Go competes with injectable mealtime and long-acting insulins from companies such as Novo Nordisk and Sanofi, as well as GLP-1 analog injection products from AstraZeneca PLC, Eli Lilly and Company, and Novo Nordisk A/S. V-Go's wearable patch system offers a convenience advantage.
• Furoscix competes with therapies for heart failure from a broad range of companies including Abbott Laboratories, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Medtronic, Novartis, Pfizer, Roche, Sanofi, and Takeda Pharmaceutical Company. Furoscix's FDA approval as the first subcutaneous loop diuretic for at-home intravenous-equivalent diuresis provides a unique market position compared to traditional hospital-administered treatments.
• Tyvaso DPI, for PAH and PH-ILD, faces a direct competitive threat from United Therapeutics' own developing product, Tresmi, a treprostinil solution for a soft mist inhaler, which United Therapeutics claims could significantly reduce coughing, a known side effect of dry-powder inhalers. This internal competition from a partner is a notable industry dynamic.
• MannKind's total illness and injury incidence rate of 0.3 per 100 employees in 2025 is significantly better than the 2024 industry average of 1.7, and its DART incident rate of 0.2 per 100 employees is also better than the industry average of 1.2, indicating strong occupational health and safety performance.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to legal proceedings and claims arising in the ordinary course of business, but does not anticipate the final disposition of any matters will have a material adverse effect on results of operations, financial position, or cash flows.

Related Party Transactions

• The company has an Insulin Supply Agreement with Amphastar France Pharmaceuticals S.A.S. (Amphastar), which is also a co-promotion partner for Baqsimi.
• The company has a License and Collaboration Agreement and Commercial Supply Agreement with United Therapeutics Corporation (UT) for Tyvaso DPI and MNKD-1501.
• In December 2023, the company sold a 1% royalty on future net sales of Tyvaso DPI to Sagard Healthcare Partners Funding Borrower SPE 2, LP.
• The company has a financing liability related to the sale-leaseback transaction of its Danbury, CT manufacturing facility with an affiliate of Creative Manufacturing Properties.
• The company has a Blackstone Credit Facility with Blackstone Alternative Credit Advisors LP.
• The company previously had a convertible note with The Mann Group LLC, which was discharged and terminated in April 2024.

Stakeholder Impact

• **Shareholders**: Experience dilution from equity issuances (ESPP, RSU vesting, potential ATM offerings) and potential volatility due to market, economic, and geopolitical conditions. Net income decline in 2025 may concern investors despite revenue growth. The Blackstone Credit Facility's restrictive covenants could limit future strategic flexibility. Dependence on United Therapeutics' commercial strategy for Tyvaso DPI introduces significant risk.
• **Employees**: Benefit from a comprehensive Total Rewards Program including competitive salaries, annual bonuses, equity awards, health and wellness programs, paid time off, 401(k) matching, and an ESPP. The scPharma acquisition and Pulmatrix transaction led to increased headcount and bolstered research capabilities. Strong occupational health and safety performance benefits employee well-being.
• **Customers (Patients & Healthcare Providers)**: Benefit from continued commercialization of Afrezza, Furoscix, and V-Go, addressing diabetes, heart failure, and chronic kidney disease. Potential new approvals for Afrezza in pediatric patients and Furoscix ReadyFlow Autoinjector could expand treatment options. The company's commitment to ethical marketing and drug safety ensures product quality and appropriate use.
• **Suppliers**: Continued demand for raw materials and components for Afrezza, Tyvaso DPI, Furoscix, and V-Go. However, reliance on single-source suppliers creates risk for both the company and its suppliers if demand or supply chain issues arise.
• **Creditors (Blackstone, Senior Convertible Note Holders)**: The Blackstone Credit Facility provides significant debt, increasing interest expense and leverage. The company's ability to meet liquidity needs and debt obligations is critical. The conversion of senior convertible notes into common stock impacts the debt structure.

Next Steps

• FDA review of sBLA for Afrezza in children and adolescents, with a PDUFA target action date of May 29, 2026.
• FDA review of sNDA for Furoscix ReadyFlow Autoinjector, with a PDUFA target action date of July 26, 2026.
• Expected top-line data from the Phase 1b study of MNKD-201 in early 2H 2026.
• Expected first patient enrollment in the global Phase 2 study of MNKD-201 in Q2 2026.
• United Therapeutics anticipates shifting primary manufacturing for Tyvaso DPI to its own facility beginning in 2026, with MannKind continuing as a secondary manufacturer.
• United Therapeutics plans to file for approval of Tresmi within the year and launch commercially in the following year.
• MannKind will continue to evaluate the feasibility of formulating bumetanide as a dry-powder for oral inhalation (MNKD-701 program).
• The company will continue to monitor and explore strategies to mitigate risks related to ongoing changes in tariff policy by the U.S. government.
• Management plans to integrate scPharma into the company's internal control framework and include it in the assessment of internal control over financial reporting beginning with the year ending December 31, 2026.

Key Dates

Recommendation

MannKind demonstrates strong revenue growth and strategic expansion through acquisitions like scPharma, diversifying its product portfolio and pipeline. The potential FDA approvals for Afrezza pediatric use and Furoscix ReadyFlow Autoinjector in 2026 represent significant near-term catalysts. However, the substantial increase in operating expenses, leading to a decline in net income, and the significant reliance on United Therapeutics for Tyvaso DPI royalties, especially with UT's plans for a potentially competitive product (Tresmi), introduce considerable uncertainty. The increased debt from the Blackstone Credit Facility also adds financial risk. Given these mixed signals—strong top-line growth and pipeline potential balanced against profitability concerns, increased expenses, and partnership risks—a 'hold' recommendation is appropriate for seasoned investors to monitor the execution of pipeline milestones and the impact of competitive dynamics.

Keywords

Biopharmaceutical, Cardiometabolic, Orphan Lung Diseases, Afrezza, Furoscix, V-Go, Tyvaso DPI, Inhaled Insulin, Pulmonary Hypertension, Heart Failure, Chronic Kidney Disease, Drug-Device Combination, Technosphere, FDA Approval, Clinical Trials, Pharmaceutical Manufacturing, SEC Filing, 10-K, Biotechnology, Diabetes, Edema, IPF, MNKD-201, MNKD-1501, Blackstone Credit Facility, scPharmaceuticals, United Therapeutics